Abstract | STUDY OBJECTIVES: To study the impact of filgrastim 5 microg/kg given once/day through absolute neutrophil count (ANC) recovery on the duration of grade 4 neutropenia (ANC < 0.5 x 10(3)/mm3) and time to ANC recovery. Additional objectives were to study the average number of filgrastim injections/cycle required to achieve ANC recovery and differences in outcome by cycle. DESIGN: Combined analysis of two double-blind, randomized, multicenter trials. PATIENTS: MEASUREMENTS AND MAIN RESULTS: All patients but one were evaluable for efficacy end points. Mean +/- SD duration of grade 4 neutropenia was 1.7 +/- 1.3 days in cycle 1; the duration decreased in cycles 2-4 to between 1.0 and 1.2 days. Fifty percent of patients had ANC recovery to 10 x 10(3)/mm3 or greater by day 11 of the cycle, and 90% by day 13, corresponding to 10 and 12 days of filgrastim administration, respectively. Across all cycles, the mean +/- SD number of filgrastim injections/cycle was 10.51 +/- 1.70, with little variation among cycles. CONCLUSION:
|
Authors | Luis A Meza, Michael D Green, James R Hackett, Theresa A Neumann, Frankie A Holmes |
Journal | Pharmacotherapy
(Pharmacotherapy)
Vol. 23
Issue 11
Pg. 1424-31
(Nov 2003)
ISSN: 0277-0008 [Print] United States |
PMID | 14620389
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Meta-Analysis, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Taxoids
- Granulocyte Colony-Stimulating Factor
- Docetaxel
- Doxorubicin
- Filgrastim
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Breast Neoplasms
(blood, drug therapy)
- Docetaxel
- Doxorubicin
(administration & dosage, adverse effects)
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(pharmacology, therapeutic use)
- Humans
- Male
- Middle Aged
- Neutropenia
(blood, chemically induced, drug therapy)
- Neutrophils
(cytology, drug effects)
- Recombinant Proteins
- Taxoids
(administration & dosage, adverse effects)
- Time Factors
|